IMPORTANCE Ototoxicity is an irreversible direct and late effect of certain childhood cancer treatments. Audiologic surveillance during therapy as part of the supportive care pathway enables early detection of hearing loss, decision-making about ongoing cancer treatment, and, when applicable, the timely use of audiologic interventions. Pediatric oncologic clinical practice and treatment trials have tended to be driven by tumor type and tumor-specific working groups. Internationally accepted standardized recommendations for monitoring hearing during treatment have not previously been agreed on. OBJECTIVE To provide standard recommendations on hearing loss monitoring during childhood cancer therapy for clinical practice. METHODS An Ototoxicity Task Force was formed under the umbrella of the International Society of Paediatric Oncology, consisting of international audiologists, otolaryngologists, and leaders in the field of relevant pediatric oncology tumor groups. Consensus meetings conducted by experts were organized, aimed at providing standardized recommendations on age-directed testing, timing, and frequency of monitoring during cancer treatment based on literature and consensus. Consensus statements were prepared by the core group, adapted following several videoconferences, and finally agreed on by the expert panel. FINDINGS The consensus reached was that children who receive ototoxic cancer treatment (platinum agents, cranial irradiation, and/or brain surgery) require a baseline case history, monitoring of their middle ear and inner ear function, and assessment of tinnitus at each audiologic follow-up. As a minimum, age-appropriate testing should be performed before and at the end of treatment. Ideally, audiometry with counseling before each cisplatin cycle should be considered in the context of the individual patient, specific disease, feasibility, and available resources. CONCLUSIONS AND RELEVANCE This is an international multidisciplinary consensus report providing standardized supportive care recommendations on hearing monitoring in children undergoing potentially ototoxic cancer treatment. The recommendations are intended to improve the care of children with cancer and facilitate comparative research on the timing and development of hearing loss caused by different cancer treatment regimens.

中文翻译：

---

儿童癌症治疗期间听力学监测的年龄适当测试、时间和频率的建议：国际儿科肿瘤支持治疗共识报告。

重要性 耳毒性是某些儿童癌症治疗的不可逆转的直接和迟发效应。作为支持性护理途径的一部分，治疗期间的听力学监测能够及早发现听力损失，对正在进行的癌症治疗做出决策，并在适用时及时使用听力学干预措施。儿科肿瘤临床实践和治疗试验往往由肿瘤类型和肿瘤特异性工作组驱动。在治疗期间监测听力的国际公认标准化建议以前尚未达成一致。目的 为临床实践中儿童癌症治疗期间的听力损失监测提供标准建议。方法 在国际儿科肿瘤学会的保护下成立了一个耳毒性工作组，由国际听力学家、耳鼻喉科医生和相关儿科肿瘤肿瘤组领域的领导者组成。组织了专家召开的共识会议，旨在根据文献和共识，就癌症治疗期间的年龄导向检测、时间和监测频率提供标准化建议。共识声明由核心小组准备，经过多次视频会议进行调整，最终得到专家小组的同意。结果 达成的共识是接受耳毒性癌症治疗（铂类药物、颅脑照射和/或脑部手术）的儿童需要基线病史，监测他们的中耳和内耳功能，并在每次听力学随访时评估耳鸣——向上。至少，应在治疗前和治疗结束时进行适合年龄的测试。理想情况下，应根据个体患者、特定疾病、可行性和可用资源来考虑在每个顺铂周期之前进行听力测量和咨询。结论和相关性 这是一份国际多学科共识报告，为接受潜在耳毒性癌症治疗的儿童的听力监测提供标准化的支持性护理建议。这些建议旨在改善对癌症儿童的护理，并促进对不同癌症治疗方案引起的听力损失的时间和发展进行比较研究。具体疾病、可行性和可用资源。结论和相关性 这是一份国际多学科共识报告，为接受潜在耳毒性癌症治疗的儿童的听力监测提供标准化的支持性护理建议。这些建议旨在改善对癌症儿童的护理，并促进对不同癌症治疗方案引起的听力损失的时间和发展进行比较研究。具体疾病、可行性和可用资源。结论和相关性 这是一份国际多学科共识报告，为接受潜在耳毒性癌症治疗的儿童的听力监测提供标准化的支持性护理建议。这些建议旨在改善对癌症儿童的护理，并促进对不同癌症治疗方案引起的听力损失的时间和发展进行比较研究。